ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

2024-9-1

Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple negative breast cancer patients

2024-9-1

SDHA related phaeochromocytoma and paraganglioma: review and clinical management

2024-8-1

Endocrine cancer trends 1990–2021: global disparities and health inequalities

2024-8-1

Promoter mutation-independent TERT expression is related to immune-enriched milieu in papillary thyroid cancer

2024-8-1

Nutrition, GH/IGF-I signaling, and cancer

2024-8-1

Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center

2024-8-1

Management of advanced high grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature

2024-8-1

MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy

2024-8-1

Thyroid dysfunction caused by immune-checkpoint-inhibitors improves cancer outcomes

2024-7-1

Distinct transcriptional and prognostic impacts of TERT promoter mutations C228T and C250T in papillary thyroid carcinoma

2024-7-1

Ectopic adrenocorticotropic hormone syndrome in patients with olfactory neuroblastoma

2024-7-1

A pilot study of the immune microenvironment of GI neuroendocrine carcinoma

2024-7-1

Insights on Epidemiology, Morbidity and Mortality of Cushing’s Disease in Northern Ireland

2024-6-18

Genetic variants and down-regulation of CACNA1H in pheochromocytoma

2024-6-12

Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy

2024-6-3

Disease relapse in relation to lymph node sampling in lung carcinoid patients

2024-6-1

Treatment of Advanced BP-NETS with Lanreotide Autogel/Depot vs Placebo: the Phase III SPINET Study

2024-6-1

AGEs induce MMP-9 promoter demethylation through the GADD45α-mediated BER pathway to promote breast cancer metastasis in patients with diabetes

2024-6-1

Changes in categorization or nomenclature within Neuroendocrine Tumours

2024-5-22

EPAS-1-related pheochromocytoma/paraganglioma: How common and how aggressive?

2024-5-20

The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis

2024-5-20

Advancements and Challenges in Pheochromocytoma and Paraganglioma Research: A Collection of Insights

2024-5-17

Genotype-specific development of MEN 2 constituent components in 683 RET carriers

2024-5-16

Pegvisomant or pasirotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

2024-5-7

Glucagon and insulin: 100 years young

2024-5-1

GPNMB promotes tumor growth and is a biomarker for lymphangioleiomyomatosis

2024-4-1

Neuropilin-2 and soluble neuropilin-2 in neuroendocrine neoplasms

2024-4-1

Patient reported burden associated with pheochromocytoma/paraganglioma diagnosis

2024-4-1

Importance of 3β-hydroxysteroid dehydrogenases and their clinical use in prostate cancer

2024-4-1

A zebrafish xenotransplant model of anaplastic thyroid cancer to study the tumor microenvironment and innate immune cell interactions in vivo

2024-4-1

Genetic disorders and insulinoma/glucagonoma

2024-3-28

HSPB1 promotes tumor invasion by inducing angiogenesis in PitNETs

2024-3-8

Clinical and basic research implications of the article ‘IGF-1 axis changes with ADT and docetaxel in metastatic prostate cancer’

2024-3-5

ERRATUM: Mutational landscape of non-functional adrenocortical adenomas

2024-3-1

RAB5A polarizes macrophage and promotes breast cancer

2024-3-1

Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma

2024-2-16

Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy

2024-2-8

Bioengineered in vitro three-dimensional tumor models in endocrine cancers

2024-2-2

Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the United States, 2000–2020: a population-based retrospective cohort study

2024-2-1

Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients

2024-1-23

Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms

2024-1-22

Immunotherapy for endocrine tumours: a clinician’s perspective

2024-1-18

Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma

2024-1-15

Immunophenotyping with high-dimensional flow cytometry identifies Treg cell subsets associated with recurrence in papillary thyroid carcinoma

2024-1-12

Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms

2024-1-12

Growth hormone and radiation therapy: friend, foe, or both?

2024-1-4

Sexual dimorphism in medullary thyroid cancer aggressiveness

2024-1-4

Acknowledgement to reviewers

2024-1-1

Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?

2024-1-1